Mayo Finds New Path to Treat Crohn's Disease

Scientists at Mayo Clinic have cracked open a mystery that's puzzled doctors for years: why standard treatments fail nearly half of all Crohn's disease patients.

The team discovered that a molecule called ST8Sia6 acts as a crucial regulator of immune activity in the gut. When this molecule is missing or reduced, inflammatory immune cells flood the intestines, triggering the painful symptoms that affect nearly 3 million Americans with inflammatory bowel disease.

"The normal function of ST8Sia6 in the gut had not been previously described," says Mayo Clinic immunology researcher Virginia Shapiro, who led the study published in Cell Reports. Her team found the molecule keeps immune cells in a balanced, steady state.

The discovery happened when researchers noticed something intriguing in an international health database. A single mutation in the gene for ST8Sia6 appeared more frequently in people with Crohn's disease than in the general population.

Graduate student Sydney Crotts and her team tested their hunch using preclinical models lacking the ST8Sia6 gene. The results were dramatic: immune cells gathered in massive numbers in the small intestine, creating a perfect storm for inflammation.

The Bright Side

This finding explains why existing medications targeting TNF-alpha work wonderfully for some patients but leave others struggling. The ST8Sia6 pathway appears to be completely separate from the routes current drugs take, meaning doctors may soon have an entirely new tool in their arsenal.

For patients whose symptoms don't improve with existing treatments, this research offers genuine hope. The team's preclinical models showed inflammation that didn't respond to TNF-alpha medication, mirroring what happens in resistant patients.

"We think this might be a model of what's happening in patients with Crohn's disease who have a baseline of immune cells and are basically fine until they encounter a trigger and have a flare," Crotts explains.

The research builds on earlier work from Shapiro's lab, which showed ST8Sia6 helping tumors evade immune destruction and protecting insulin-producing cells in diabetes. Each discovery reveals another facet of how this molecule orchestrates immune responses throughout the body.

While further studies are needed before this reaches patients, researchers now have a clear path forward to develop treatments targeting this newly understood pathway. For the millions living with inflammatory bowel disease, that path leads somewhere it hasn't before: toward relief that current medicines can't provide.